News
-
How small changes are making big strides in prison harm reduction
One in four people in Canadian federal prisons have been previously exposed to hepatitis C. Hepatitis C can…
-
Newborn screening for CMV catches overlooked infections
Somewhere between 1 in every 200 to 800 babies are born infected with cytomegalovirus (CMV). If undiagnosed, it…
-
Hepatitis C cure does not remove all risks, CTN investigators find
CTN Investigators Drs. Naveed Janjua (Canadian lead) and Sofia Bartlett, along with a team of researchers from Canada…
Resources
Our Resource Library is a place to share documents, videos, and training resources about HIV and STBBI research and related topics.
-
Types
Public Health Agency of Canada
This study aimed to provide the first national estimates of HBV prevalence and unawareness, and to update estimates of HCV incidence, prevalence, and unawareness in the general population and key populations in Canada for 2021. Progress towards elimination targets for 2025, namely incidence, awareness, mortality, and HBV vaccination, was also assessed
-
Resource CategoriesTypes
Treatment Access Group (TAG)
Welcome to the 2025 Pipeline Report. TAG’s annual review provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).
Studies
The CTN+ supports clinical trials, implementation science projects, and non-interventional research of the highest scientific and ethical standards.
-
CTN 337: The FAST-TRACK Study
An open-label individual-level randomized controlled trial to compare point of care HCV RNA testing and nurse-led rapid treatment initiation to standard of care to enhance treatment uptake in persons with hepatitis C in a transient correctional setting
-
CTN 260: Raltegravir switch study
A randomized prospective open-label study of switching to raltegravir based antiretroviral therapy (ART) compared to maintaining ritonavir boosted protease inhibitor-based ART on liver fibrosis progression in HIV-HCV co-infected individuals
-
CTN 222: Canadian co-infection cohort
A prospective clinical cohort of HIV and hepatitis C virus co-infected patients
-
CTN 194: Peg-interferon and citalopram in co-infection (PICCO)
Trial of Citalopram for the Prevention of Depression
-
CTN 227: Hepatitis C therapeutic vaccine
Open label, dose escalating phase I/II study of TG4040 (MVA-HCV) in patients chronically infected with hepatitis C virus (Genotype I) who relapsed from previous pegylated interferon/ribavirin treatment
Publications
Our researchers and trainees have produced hundreds of peer-reviewed publications in a wide range of HIV- and STBBI-related areas.